Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A

Clinical trial NCT05500807 · RECRUITING

Trial details

NCT number: NCT05500807
Sponsor: Bleeding and Clotting Disorders Institute Peoria, Illinois
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Von Willebrand Disease, Type 3 Concomitant VWD and Hemophilia

Start date: 2022-11-01
Primary completion: 2027-06-01
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.